IVD China last week: Dian Diagnostics & Quest Diagnostics, MGI, GE Healthcare, Snibe, Orient Gene

Dian Diagnostics introduces this innovative technology from Quest Diagnostics

On June 13, Dian Diagnostics announced that it has reached an agreement with Quest Diagnostics, a leading global provider of clinical medical diagnostic services, to introduce relevant technologies to develop and provide blood-based Alzheimer's Disease (AD) clinical application research services in China.

Dian Diagnostics will introduce a Quest AD-Detect® beta-amyloid 42/40 blood test based on IP-LC-MS/MS technology. This test is analytically validated to help assess AD risk. Specifically, it helps physicians assess the ratio of two amyloid beta proteins in plasma, i.e., Aβ42/Aβ40, and monitor the trend of Aβ over time with a single tube of blood sample, thereby assessing the risk of AD progression. 

In addition to providing a prognosis regarding the risk of AD, the assay also helps to identify patients who may benefit from further interventions. The IP-LC-MS/MS technique uses specific antibodies to isolate and enrich Aβ peptides from plasma by protein immunoprecipitation, and utilizes high-sensitivity liquid chromatography-mass spectrometry to identify and quantify individual Aβ isoforms, including Aβ42 and Aβ40, providing the advantages of high sensitivity and precise quantitative analysis and other advantages. The ratio of Aβ42 to Aβ40 can be accurately determined by IP-LC-MS/MS, which is important for assessing the progression and diagnosis of AD and is as effective as conventional cerebrospinal fluid testing and PET imaging.

MGI's new European headquarters officially opens, building a globalized service system

On June 2, MGI officially opened its new European headquarters in Berlin, Germany, to fully support the development of life science and technology in the region. The opening ceremony was attended by Dejian Yu, President of MGI, Dr. Rade Drmanac, Chief Scientist of MGI, and Dr. Hou Yong, Head of Europe and Africa of MGI.

MGI's new European headquarters occupies an area of over 600 square meters and is equipped with MGI's latest technologies and products, including an exclusive Customer Experience Center (CEC) and a state-of-the-art Frontier Laboratory for Histology (DCS Lab), which will be further expanded in the future. It will also serve as an early experience and testing site for MGI's new technologies and products to better serve and support European partners and customers. The new headquarters is conveniently located near Berlin Brandenburg Airport and is open to the public for tours.

At the opening, MGI also launched the "DNBSEQ-G400 (MGISEQ-2000 in China) Developer Program" for the first time, which is designed to support European researchers to develop and implement personalized and customized workflows for exploring the capabilities of spatial transcriptomics, multiplexed immunofluorescence analysis, and other multi-omics analysis capabilities.

GE Healthcare and Hainan Provincial People's Government signed a memorandum of strategic cooperation

Recently, GE Healthcare and the People's Government of Hainan Province signed a strategic cooperation memorandum in New York. Before the signing, Liu Xiaoming, Deputy Secretary of the Hainan Provincial Party Committee and Governor of Hainan Province, met with Zhang Yihao and his entourage, Global Executive Vice President of GE Healthcare and President and CEO of GE Healthcare China, and reached a consensus on accelerating the implementation of the cooperation between the two parties to jointly promote the development of health care in Hainan Province.

As early as 2020, GE and Hainan Province reached a cooperation to actively build a comprehensive cooperation platform in the medical field, and GE Healthcare's development layout in Hainan Province has thus begun. Since 2011, GE Healthcare has held the Boao Healthcare Leadership Summit in Hainan every year, which has developed into one of the largest medical industry congresses of 1,000 people in China, and has successively influenced the landing of projects and investment projects of nearly 2 billion in scale, and the planned projects of intent are expected to reach 3 billion, involving nearly 10 medical institutions, which has injected new vitality into the local economy.

Snibe, together with Keyto Fluid and Shenzhen University, completed the acceptance of Shenzhen Science and Technology Tackling Project

Recently, Snibe joins hands with Keyto Fluid and Shenzhen University to complete a key technology research and development project (Project No. 2019N015) initiated by Shenzhen Science and Technology Innovation Commission on high pressure resistance and long-life isolation solenoid valves for medical instruments. Snibe as a medical instrument parts and components needs to use and verify the unit, Shenzhen University as a unit of higher education scientific research and exploration, Keyto Fluid as the project needs to organize and technical feasibility of the realization of the unit, the three parties to play to their respective strengths, in-depth technical integration and innovation cooperation.

In the project, program evaluation, material selection, parameter setting, reliability verification, after many reviews and discussions, the new high-pressure resistance and long life isolation solenoid valve successfully developed. This solenoid valve not only has excellent pressure resistance and durability, but also has the characteristics of fast response, low leakage, etc., which can meet the application requirements of medical instruments under various complex working conditions.

Orient Gene's Respiratory Test Receives U.S. FDA Emergency Use Authorization

Orient Gene announced that its wholly-owned subsidiary, Healgen Biotechnology, Inc. has recently obtained an Emergency Use Authorization (EUA) for Healgen COVID-19/Flu A&BAg Combo Rapid Test Cassette (Swab), which has been approved by the U.S. Food & Drug Administration (FDA). COVID-19/Flu A&BAg Combo Rapid Test Cassette (Swab) approved by the U.S. Food & Drug Administration.

Orient Gene indicated that the EUA authorization granted by FDA further improves the Company's important product categories in the U.S. market, which is conducive to the overall expansion of the U.S. market, and the Company will continue to pay attention to the dynamics of demand in the U.S. market, and actively promote the marketing and sales of the product.

​